Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study - 25/07/20
![](/templates/common/images/mail.png)
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Background |
Diseases consequence on individual work as much as consequences of being absent from work are matters of interest for decision makers.
Methods |
We analyzed lengths of absenteeism and related indirect costs for patients with a paid activity in the year following the diagnosis of early stage breast cancer, in the prospective OPTISOINS01 cohort. Both human capital and friction costs approach were considered for the valuation of lost working days (LWD). For the analysis, the friction period was estimated from recent French data. The statistical analysis included simple and multiple linear regression to search for the determinants of absenteeism and indirect costs.
Results |
93 % of the patients had at least one period of sick leave, with on average 2 period and 186 days of sick leave. 24 % of the patients had a part-time resumption after their sick leave periods, during 114 days on average (i.e. 41 LWD). Estimated indirect costs were 22,722.00 € and 7,724.00 € per patient, respectively for the human capital and the friction cost approach. In the multiple linear regression model, factors associated with absenteeism were: the invasive nature of the tumor (p = .043), a mastectomy (p = .038), a surgery revision (p = .002), a chemotherapy (p = .027), being a manager (p = .025) or a craftsman (p = .005).
Conclusion |
Breast cancer lead to important lengths of absenteeism in the year following the diagnosis, but almost all patients were able to return to work. Using the friction cost or the human capital approach in the analysis led to an important gap in the results, highlighting the importance of considering both for such studies.
Le texte complet de cet article est disponible en PDF.Abbreviations : BC, FC, HAS, HC, HTA, LWD
Keywords : Health economics, Breast cancer, Indirect costs, Absenteeism, Economic burden
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?